KKUR (ChromoCure) at $0.000001 on 05 Jan 2026: microcap tops gainers
KKUR moved to USD 0.000001 in market hours on 05 Jan 2026, putting ChromoCure, Inc. among today’s top gainers. The microcap traded between USD 0.000001 and USD 0.000002 with 17 shares changing hands, a sharp contrast with its average volume of 2,900,052. We examine why the trade occurred, what the tiny market cap of USD 8,200 and 8,200,000,000 shares outstanding mean for liquidity, and how sector context in Healthcare may shape near-term interest.
Price action and session details
The first trade printed at USD 0.000002 and the intraday range was USD 0.000001 to USD 0.000002 on the PNK exchange in the United States. The reported 1-day change was USD 0.000001 from a previous close effectively at USD 0.00000000000000000002280614, which produces an extreme percentage move on paper but should be interpreted in light of minuscule pricing and rounding.
Volume, liquidity and float dynamics
Volume was 17 shares versus an average volume of 2,900,052, highlighting near-zero liquidity despite the stock appearing as a gainer today. With 8,200,000,000 shares outstanding and a market cap of USD 8,200, a few trades can move the quote; that explains the outsized percent figures and the low relative volume metric.
Fundamentals and company snapshot
ChromoCure, Inc. (KKUR) is a Healthcare company listed on PNK in the United States that develops the Chromosomal Scanner Series 200 for cancer detection. The company reports 4 full-time employees and no recent public earnings data; EPS and P/E are not available, and revenue and balance sheet metrics are missing from the public feed.
Technical view and sector context
Technical indicators are not meaningful for KKUR given sparse trading: RSI is reported at 0.00 and MACD and ADX are 0.00 in the feed. Healthcare and the Medical – Specialties industry traded mixed today, so any sustained move in KKUR would likely need a clear fundamental catalyst or improved trading volume to validate price change.
Meyka AI stock grade and analyst framing
Meyka AI rates KKUR with a score out of 100: Score 62.75 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects scarce financial disclosure, tiny market cap (USD 8,200), and high structural volatility; these grades are informational and not investment advice.
Risks, catalysts and trading strategy
Primary risks include extreme illiquidity, lack of reported earnings, and a tiny market cap that increases manipulation risk. Potential catalysts would be verifiable clinical or corporate news, regulatory filings, or a reverse split that improves tradability. Traders should limit position size and plan exit points given the bid-ask and volume realities.
Final Thoughts
Key takeaways: KKUR stock (ChromoCure, Inc.) traded at USD 0.000001 on 05 Jan 2026 in market hours on PNK with only 17 shares changing hands and a market cap of USD 8,200. The quote moved from essentially zero to USD 0.000001 and back into the microcap range; that behavior reflects liquidity dynamics, not validated fundamental improvement. Meyka AI’s forecast model projects a yearly nominal target of USD 0.000000, which compared to the current price of USD 0.000001 implies an illustrative -100.00% shift; forecasts are model-based projections and not guarantees. For investors, the structural picture is clear: without fresh, verifiable corporate disclosure or meaningful volume, KKUR remains a speculative microcap best approached with caution and tight risk controls. For more market context visit Markets Insider and check real-time data on KKUR.
FAQs
The large percentage change is driven by tiny price levels and sparse trading. KKUR moved from a near-zero previous close to USD 0.000001 on limited volume, which inflates percentage calculations but does not indicate broad market interest.
ChromoCure, Inc. shows a market cap of USD 8,200 and 8,200,000,000 shares outstanding. Volume today was 17 shares versus a 30‑day average of 2,900,052, indicating extremely low liquidity.
Meyka AI’s grade (Score 62.75, Grade B, Suggestion: HOLD) and forecast are data-driven assessments that factor sector and metric gaps. They are informational only; investors should conduct independent research before trading KKUR.
No recent earnings or analyst price targets are available for ChromoCure, Inc. EPS and P/E are not reported in the public feed, and price target consensus is absent.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.